# US 8,278,460 B2 · Substituted benzimidazoles

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 8,278,460 B2
- Document ID: US8278460B2
- Status: Granted
- Kind: B2
- Application number: 12/905,835
- Filed: 2010-10-15
- Published: 2011-07-14
- Granted: 2012-10-02
- Earliest claimed: 2009-10-15
- Assignees: Concert Pharmaceuticals, Inc.
- Inventors: Julie F. Liu; Scott L. Harbeson
- Web page: https://patentgrep.com/patent/US8278460B2

## CPC

- C07B 59/002: {Heterocyclic compounds}
- A61P 21/00: Drugs for disorders of the muscular or neuromuscular system
- A61P 25/00: Drugs for disorders of the nervous system
- C07D 235/06: with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached in position 2
- C07B: GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR (preparation of carboxylic acid esters by telomerisation C07C67/47; telomerisation C08F)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C07D: HETEROCYCLIC COMPOUNDS (macromolecular compounds C08)

## Abstract

This invention relates to novel substituted benzimidazoles and pharmaceutically acceptable salts thereof. This invention also provides compositions comprising a compound of this invention and the use of such compositions in methods of treating diseases and conditions that are beneficially treated by administering a compound that modulates the GABAA receptor. This invention also provides novel intermediates for the preparation of the compounds of the invention, and salts thereof.

## Claims

### Claim 1

The compound of 102:
or a pharmaceutically acceptable salt thereof, wherein any atom not designated as deuterium is present at its natural isotopic abundance.

### Claim 2 (depends on 1)

A pyrogen-free pharmaceutical composition comprising a compound of claim 1 or a pharmaceutically acceptable salt of said compound; and a pharmaceutically acceptable carrier.

### Claim 3 (depends on 2)

The composition of claim 2 additionally comprising a therapeutic agent useful in the treatment of a disease or condition selected from anxiety, convulsions, skeletal muscle spasm, spasticity, athetosis, epilepsy, stiff-person syndrome, and pain.

### Claim 4 (depends on 2)

A method of treating a disease or condition selected from anxiety, convulsions, skeletal muscle spasm, spasticity, athetosis, epilepsy, stiff-person syndrome, and pain, in a subject comprising the step of administering to the subject an effective amount of a composition of claim 2.

### Claim 5 (depends on 4)

The method of claim 4, wherein the disease or condition is anxiety or convulsions.
